Novavax, Inc.
NVAX
$10.75
$0.676.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.61% | -16.64% | -42.42% | 610.30% | -69.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.61% | -16.64% | -42.42% | 610.30% | -69.69% |
| Cost of Revenue | -22.92% | -22.34% | -42.43% | -31.43% | -43.21% |
| Gross Profit | 136.16% | 32.15% | -42.41% | 1,098.71% | -642.09% |
| SG&A Expenses | -128.05% | -42.92% | -53.23% | -42.17% | -77.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.97% | -30.10% | -47.29% | -35.23% | -54.98% |
| Operating Income | 116.69% | 38.85% | -34.81% | 471.95% | 31.64% |
| Income Before Tax | 124.33% | -65.97% | -34.71% | 457.80% | 58.36% |
| Income Tax Expenses | -94.95% | 36.34% | -57.10% | -46.95% | 341.29% |
| Earnings from Continuing Operations | 121.63% | -66.84% | -34.41% | 451.51% | 54.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 121.63% | -66.84% | -34.41% | 451.51% | 54.58% |
| EBIT | 116.69% | 38.85% | -34.81% | 471.95% | 31.64% |
| EBITDA | 123.07% | 37.84% | -34.63% | 514.23% | 34.62% |
| EPS Basic | 121.32% | -64.47% | -39.93% | 405.37% | 64.94% |
| Normalized Basic EPS | 120.22% | 36.83% | -40.72% | 424.82% | 47.61% |
| EPS Diluted | 121.31% | -64.47% | -38.09% | 378.28% | 64.93% |
| Normalized Diluted EPS | 119.90% | 36.83% | -39.41% | 394.50% | 47.61% |
| Average Basic Shares Outstanding | 1.43% | 1.44% | 9.19% | 15.10% | 29.56% |
| Average Diluted Shares Outstanding | 3.08% | 1.44% | 6.85% | 26.95% | 29.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |